Compare NVTS & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVTS | IMNM |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.5B |
| IPO Year | 2020 | 2020 |
| Metric | NVTS | IMNM |
|---|---|---|
| Price | $7.88 | $17.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 17 |
| Target Price | $14.39 | ★ $35.33 |
| AVG Volume (30 Days) | ★ 12.4M | 1.5M |
| Earning Date | 11-03-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $45,916,000.00 | $6,941,000.00 |
| Revenue This Year | $4.02 | N/A |
| Revenue Next Year | $52.24 | $18,803.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.85 | $14.64 |
| 52 Week High | $34.17 | $30.06 |
| Indicator | NVTS | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 47.26 | 49.71 |
| Support Level | $7.65 | $19.47 |
| Resistance Level | $9.57 | $23.48 |
| Average True Range (ATR) | 0.60 | 1.18 |
| MACD | 0.08 | 0.47 |
| Stochastic Oscillator | 86.07 | 48.90 |
Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components. Geographically, the company operates in Hong Kong, China, Europe, the United States, Rest of Asia, and Others. The majority of revenue is generated from Hong Kong.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.